WallStSmart

Ainos Inc (AIMD)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 208419% more annual revenue ($258.90M vs $124,160). AIMD leads profitability with a 0.0% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

AIMD

Hold

40

out of 100

Grade: D

Growth: 5.3Profit: 2.5Value: 7.7Quality: 4.5
Piotroski: 3/9Altman Z: -3.45

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AIMDUndervalued (+53.1%)

Margin of Safety

+53.1%

Fair Value

$3.71

Current Price

$1.72

$1.99 discount

UndervaluedFair: $3.71Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIMD3 strengths · Avg: 8.7/10
Revenue GrowthGrowth
412.4%10/10

Revenue surging 412.4% year-over-year

PEG RatioValuation
0.938/10

Growing faster than its price suggests

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

AIMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$12.50M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Debt/EquityHealth
1.103/10

Elevated debt levels

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : AIMD

The strongest argument for AIMD centers on Revenue Growth, PEG Ratio, Price/Book. Revenue growth of 412.4% demonstrates continued momentum. PEG of 0.93 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : AIMD

The primary concerns for AIMD are EPS Growth, Market Cap, Profit Margin.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

AIMD carries more volatility with a beta of 2.32 — expect wider price swings.

AIMD is growing revenue faster at 412.4% — sustainability is the question.

Monitor SCIENTIFIC & TECHNICAL INSTRUMENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 40/100) and 43.0% revenue growth. AIMD offers better value entry with a 53.1% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ainos Inc

TECHNOLOGY · SCIENTIFIC & TECHNICAL INSTRUMENTS · USA

Ainos, Inc., a healthcare company, is dedicated to the development of medical technologies for safe and novel point-of-care testing and medical treatment for disease indications. The company is headquartered in San Diego, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?